As shown in Table 4, before BCG treatment, PD-L2 expression was positive in tumor cells and tumor-infiltrating inflammatory cells within tumor tissues from 2 (10%) and 1 (5%) of 21 BCG-resistant patients, respectively. This evidence concerns the gene PDCD1LG2 and neoplasm.